65,437 trials
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Lymphedema, Secondary · Lymphedema of Upper Limb
Primary: Recruitment Rates — 32.5; 37.5 rate of recruitment
Coronary Microvascular Dysfunction
Primary: Change From Baseline in Coronary Flow Reserve — 0.62 ratio
Muscular Atrophy, Spinal
Primary: Part 1: Selected Part 2 Dose of Risdiplam — 0.2 mg/kg
Obesity, Childhood · Feeding Behavior
Primary: Change From Baseline 3-Day Food Diary (Dietary Variety) at 3 Months — 3.66 number of unique foods
Diabetes Mellitus, Type 2
Primary: Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose…
Autosomal Dominant Osteopetrosis Type 2
Primary: Changes in Bone Resorption Markers From Baseline to 14 Weeks. — 2.2; -2.1 percentage of change
Parenteral Nutrition · Blood Stream Infection
Primary: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB) — 127; 106 Participants
Myasthenia Gravis
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) — 10; 10; 8; 3 Participants
Pain, Postoperative
Primary: SPI24 — 88.3; 116.2 units on a scale
Tobacco Use · Smoking Cessation · Smoking, Tobacco
Primary: Number of Participants With Change in Self-reported 7-day Tobacco Abstinence From Baseline to Follow-up — 15; 21 Participants
Human Papilloma Virus Infection · Stage III Squamous Cell Carcinoma of the Oropharynx · Stage IVA Squamous Cell Carcinoma of the Oropharynx
Primary: Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 — 94.5 percentage of participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months